Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $280

Benzinga · 08/04 12:35
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $245 to $280.